Natixis Ultragenyx Pharmaceutical Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Natixis holds 15,671 shares of RARE stock, worth $746,566. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,671

Holding current value

$746,566

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$40.21 - $59.36 $630,130 - $930,230	15,671 New	15,671 $870,000
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $1.1 Million - $1.47 Million	-31,600 Reduced 48.84%	33,100 $1.18 Million
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $2.42 Million - $3.37 Million	64,700 New	64,700 $2.98 Million
Q1 2022 May 13, 2022	SELL	$62.2 - $84.4 $986,678 - $1.34 Million	-15,863 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $1.48 Million - $1.77 Million	-20,143 Reduced 55.94%	15,863 $1.33 Million
Q3 2021 Nov 12, 2021	BUY	$77.92 - $102.4 $2.81 Million - $3.69 Million	36,006 New	36,006 $3.25 Million
Q2 2021 Aug 13, 2021	SELL	$92.19 - $115.71 $241,353 - $302,928	-2,618 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $17,317 - $27,172	-162 Reduced 5.83%	2,618 $298,000
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $234,632 - $493,144	2,780 New	2,780 $385,000

Others Institutions Holding RARE

# of Institutions

322

Shares Held

85.5M

Call Options Held

668K

Put Options Held

288K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$474 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$267 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$244 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$198 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$146 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.34B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account